Top
image credit: Maryland GovPics / Flickr

Novavax Says U.S. Will Pause Funding for Production of Its Vaccine

Novavax, the Maryland firm that won a $1.75 billion federal contract to develop and produce a coronavirus vaccine, said on Thursday that the federal government would not fund further production of its vaccine until the company resolves concerns of federal regulators about its work.

The firm’s disclosure came in a quarterly filing with the Securities and Exchange Commission. The Trump administration agreed to buy 110 million doses of vaccine from Novavax as part of its crash vaccine development program.

Read More on The New York Times